NASDAQ:ACRS Aclaris Therapeutics (ACRS) Stock Price, News & Analysis $2.17 -0.03 (-1.36%) Closing price 04:00 PM EasternExtended Trading$2.12 -0.04 (-2.07%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Aclaris Therapeutics Stock (NASDAQ:ACRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aclaris Therapeutics alerts:Sign Up Key Stats Today's Range$2.11▼$2.2150-Day Range$2.20▼$3.9452-Week Range$0.95▼$5.17Volume726,131 shsAverage Volume868,397 shsMarket Capitalization$155.00 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingBuy Company OverviewAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Read More… Aclaris Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks78th Percentile Overall ScoreACRS MarketRank™: Aclaris Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 171st out of 965 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingAclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAclaris Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Aclaris Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.81) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aclaris Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.49% of the outstanding shares of Aclaris Therapeutics have been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aclaris Therapeutics has recently increased by 15.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.49% of the outstanding shares of Aclaris Therapeutics have been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aclaris Therapeutics has recently increased by 15.63%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.47 News SentimentAclaris Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Aclaris Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ACRS on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,499,998.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Aclaris Therapeutics is held by insiders.Percentage Held by Institutions98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aclaris Therapeutics' insider trading history. Receive ACRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRS Stock News HeadlinesAclaris Therapeutics announces publication describing properties of ATI-2138February 12 at 6:27 PM | markets.businessinsider.comNew Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3February 12 at 6:50 AM | globenewswire.comUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driving a hidden gold market boom. Garrett Goggin, a renowned precious metals expert with 20+ years of experience, reveals 5 explosive investment opportunities set to explode in this new era. Backed by triple-digit returns in 2024, Garrett’s insights show you how to position yourself for wealth in 2025. Don’t wait—these opportunities can disappear fast!February 12, 2025 | Golden Portfolio (Ad)Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' MoleculeFebruary 11 at 7:21 PM | seekingalpha.comAclaris Therapeutics (NASDAQ:ACRS) Cut to "Sell" at StockNews.comFebruary 11 at 1:13 AM | americanbankingnews.comResearch Analysts Set Expectations for ACRS FY2025 EarningsFebruary 8, 2025 | americanbankingnews.comAclaris Therapeutics forms new Scientific Advisory BoardJanuary 30, 2025 | msn.comAclaris Therapeutics Announces Formation of New Scientific Advisory BoardJanuary 30, 2025 | globenewswire.comSee More Headlines ACRS Stock Analysis - Frequently Asked Questions How have ACRS shares performed this year? Aclaris Therapeutics' stock was trading at $2.48 at the beginning of the year. Since then, ACRS stock has decreased by 12.5% and is now trading at $2.17. View the best growth stocks for 2025 here. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.03. The biotechnology company had revenue of $4.35 million for the quarter, compared to analysts' expectations of $8.31 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 40.26% and a negative net margin of 136.65%. Who are Aclaris Therapeutics' major shareholders? Top institutional investors of Aclaris Therapeutics include Connor Clark & Lunn Investment Management Ltd. (1.27%), Geode Capital Management LLC (1.11%), Peapod Lane Capital LLC (0.57%) and Assenagon Asset Management S.A. (0.56%). Insiders that own company stock include Braden Michael Leonard, Neal Walker, Anand Mehra, Andrew N Schiff, Joseph Monahan, James Loerop, Douglas J Manion, Kevin Balthaser and Frank Ruffo. View institutional ownership trends. How do I buy shares of Aclaris Therapeutics? Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/06/2024Today2/12/2025Next Earnings (Estimated)2/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACRS CUSIPN/A CIK1557746 Webwww.aclaristx.com Phone(484) 324-7933Fax484-320-2344Employees100Year Founded2012Price Target and Rating Average Stock Price Target$11.00 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+405.7%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,480,000.00 Net Margins-136.65% Pretax Margin-138.00% Return on Equity-40.26% Return on Assets-31.71% Debt Debt-to-Equity RatioN/A Current Ratio7.03 Quick Ratio7.03 Sales & Book Value Annual Sales$31.25 million Price / Sales4.97 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book0.98Miscellaneous Outstanding Shares71,430,000Free Float66,859,000Market Cap$155.36 million OptionableOptionable Beta0.50 Social Links 7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ACRS) was last updated on 2/12/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored New Options "Trading GPS" = 91% Win-RateThink of it as GPS navigation for the options market... Even traders who previously found options "too comp...Eagle Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMarket down? Do this now.The Trump administration's new tariffs have already begun to shake the economy. The impact is real, and the cl...Colonial Metals | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredMust-See: Trump’s Shocking AI AnnouncementIf you have any investments in AI stocks or are interested in AI… Please take a moment to review the detail...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.